Vertaling van "age trial " (Nederlands → Frans) :

trial 1991) Based on 8 RCT’s ; 4 adequately randomised ( A.R) : Canada 1980 a and b, Malmo I and UK AGE trial 1991, 4 suboptimally randomised (Sub.R) : New York 1963, Two County 1978, Stockholm 1980, Göteborg 1982
Based on 8 RCT’s of fair quality (New York 1963, Malmo I and II, Two County 1978, Canada 1980, Stockholm 1980, Göteborg 1982, UK AGE trial 1991) Based on 8 RCT’s ; 4 adequately randomised ( A.R) : Canada 1980 a and b, Malmo I and UK AGE trial 1991, 4 suboptimally randomised (Sub.R) : New York 1963, Two County 1978, Stockholm 1980, Göteborg 1982

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

De andere studies werden uitgevoerd in Canada (deel a en b) 19 en in het Verenigd Koninkrijk (Edinburgh, UK AGE Trial) 8, 20 .
Les autres essais ont été réalisés au Canada (partie a et b) 20 et au Royaume-Uni (Edinburgh, UK AGE Trial) 9, 21 .

Office de la Naissance et de l'Enfance odds ratio over-the-counter papanicolou plasma protein A polymerase chain reaction Public Health Laboratory Service pregnancy-induced hypertension proton pump inhibitor positive predictive value premature rupture of membranes routine antenatal anti-D prophylaxis Royal College of Obstetricians and Gynaecologists randomised controlled trial eferences rhesus D recombinant immunoblot assay Rijksinstituut voor Ziekte- en Invaliditeitsverzekering ribonucleic acid random plasma glucose rapid plasmin reagin test relative risk reagent strip testing standard deviation single entry two step symphysis-fundal height small for gestational age Scottish Intercollegiate Guidelines Network sexueel overdraagbare aandoening Society of Obstetricians and Gynaecologists of Canada symphysis pubis dysfunction Treponema pallidum haemagglutination assay thyroïd stimulating hormone nconjugated oestriol United Kingdom United States Centers for Disease Control and
oral glucose tolerance test Office de la Naissance et de l'Enfance odds ratio over-the-counter papanicolou plasma protein A polymerase chain reaction Public Health Laboratory Service pregnancy-induced hypertension proton pump inhibitor positive predictive value premature rupture of membranes routine antenatal anti-D prophylaxis Royal College of Obstetricians and Gynaecologists randomised controlled trial eferences rhesus D recombinant immunoblot assay Rijksinstituut voor Ziekte- en Invaliditeitsverzekering ribonucleic acid random plasma glucose rapid plasmin reagin test relative risk reagent strip testing standard deviation single entry two step symphysis-fundal height small for gestational age Scottish Intercollegiate Guidelines Network sexueel overdraagbare aandoening Society of Obstetricians and Gynaecologists of Canada symphysis pubis dysfunction Treponema pallidum haemagglutination assay thyroïd stimulating hormone nconjugated oestriol United Kingdom United States Centers for Disease Control and Prevention US Preventive Services Task Force ultrasound scan urinary tract infection Veneral Disease Research Laboratory (test for syphilis) vaginal examination Vlaamse Organisaties van Vroedvrouwen Vlaamse Vereniging voor Obstetrie en Gynaecologie Wereldgezondheidsorganisatie World Health Organization weighted mean difference Wetenschappelijke Vereniging van Vlaamse Huisartsen

17. Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L, et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization.
17. Tabar L, Dean PB, Kaufman CS, Duffy SW, Chen HH. A new era in the diagnosis of breast cancer.

16. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.
17. Miller A, Baines C, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years.

Clinical trials are underway in other age groups, including as young as from two months, to protect against the serogroups A, C, W-135 and Y found with this often-fatal bacterial infection.
Des essais cliniques sont en cours dans d’autres tranches d’âges, dès l’âge de deux mois, pour les protéger contre les sérogroupes A, C, W-135 et Y que l’on trouve dans cette maladie bactérienne souvent mortelle.

Trials are underway in other age groups, including as young as two months, to protect against serogroups A, C, W-135 and Y found with this serious bacterial infection.
Des essais sont en cours dans d’autres tranches d’âges, dès l’âge de deux mois, pour les protéger contre les sérogroupes A, C, W-135 et Y que l’on trouve dans cette maladie bactérienne sévère.

Gebruikte afkortingen: 2-3-DPG = 2,3-diphosphoglyceraat; ACTH = adrenocorticotrofin; AGE = advanced glycation end products; ATP = adenosine trifosfaat; CPD(A) = citraat fosfaat dextrose (adenine); EC = erytrocytenconcentraat; ECC = extracorporele circulatie; GvHD = graft versus host disease; H 2 O 2 = waterstofperoxyd; ICAM = inter-cellular adhesion molecule; ICU = intensive care unit; IgG = immunoglobuline G; IL = interleukine; LDH = laktaat dehydrogenase; MODS = multiple organ dysfunction syndrome, multi-orgaanfalen; NO = oxyde nitrique; NTBI = nontransferrin-bound iron; PICU = pediatric intesnsive care unit; PgE 2 = prostaglandine E 2 ; pO 2 = partielle zuurstofdruk; PS = fosfatidylserine; RAGE = advanced glycation end products receptor; RCT = randomised controled trial, gerandomiseerde gecontroleerde studie; ROS = reactive oxygen species; SIRS = systemic inflammatory response syndrome, systemisch inflammatoir responssyndroom; SNO = nitrosothiol; TNF = tumor necrosis factor; TRALI = transfusion related acute lung injury; VCAM = vascular cell adhesion molecule; VO 2 = zuurstofverbruik.
Abréviations utilisées: 2-3-DPG = 2,3-diphosphoglycérate; ACTH = adrénocorticotrophine; AGE = advanced glycation end products; ATP = adénosine triphosphate; CE = concentré érythrocytaire; CEC = circulation extra-corporelle; CPD(A) = citrate phosphate dextrose (adénine); GPIIb/IIIa = glycoprotéine IIb/IIIa; GvHD = graft versus host disease; H 2 O 2 = peroxyde d’hydrogène; ICAM = inter-cellular adhesion molecule; ICU = intensive care unit; IgG = immunoglobuline G; IL = interleukine; LDH = lactate déshydrogénase; MODS = multiple organ dysfunction syndrome, syndrome de défaillance polyviscérale; NO = oxyde nitrique; NTBI = nontransferrin-bound iron; PICU = pediatric intensive care unit; PgE 2 = prostaglandine E 2 ; pO 2 = pression partielle d’oxygène; PS = phosphatidylsérine; RAGE = récepteur d’advanced glycation end products; RCT = randomised controled trial, étude randomisée contrôlée; ROS = reactive oxygen species; SIRS = systemic inflammatory response syndrome, syndrome de réponse inflammatoire systémique; SNO = nitrosothiol; TNF = tumour necrosis factor, facteur de nécrose tumorale; TRALI = transfusion related acute lung injury; VCAM = vascular cell adhesion molecule; VO 2 = consommation d’oxygène.

57. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.
56. Van Dijck JA, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65.